Corner Therapeutics Research Opens Door to Universal Flu Vaccine and Expands Promise for Cancer Immunotherapy Corner Therapeutics, a biotechnology company specializing in in vivo T cell modulation and immunotherapy, has announced groundbreaking findings that could reshape the future of vaccination…
Nature Medicine Publishes Phase 3 Data on Pridopidine, Offering Hope in Early-Stage Huntington’s Disease Prilenia Therapeutics B.V., a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases, together with its partner Ferrer, announced a significant milestone in the scientific and medical understanding…
Texas Expands Medical Cannabis Access with House Bill 46: A New Era for Patient For thousands of Texans who live each day with the burden of chronic pain, traumatic brain injuries, Crohn’s disease, cancer, and other serious conditions, September 1,…
Hope Biosciences Receives FDA RMAT Designation for Stem Cell Therapy in Relapsing-Remitting Multiple Sclerosis Hope Biosciences, a leading U.S.-based stem cell banking and cellular therapeutics manufacturer, has announced a major regulatory milestone that could reshape the future of treatment for…
Devonian Health Group Provides Strategic Corporate Update and Clarifies Details of Private Placement Financing Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for inflammatory and fibrotic diseases,…
Ifinatamab Deruxtecan Receives Breakthrough Therapy Designation from FDA for Pretreated Extensive-Stage Small Cell Lung Cancer The oncology research landscape took a significant step forward this week with the announcement that ifinatamab deruxtecan (I-DXd), an investigational antibody-drug conjugate (ADC), has been…
Grove Biopharma to Showcase Breakthrough Bionic Biologics™ at ACS Fall 2025 Symposium on Materials Biology Grove Biopharma, a private biotechnology company advancing an innovative therapeutic approach it calls Bionic Biologics™, announced that it will present updates on its research at…
AstraZeneca Launches FluMist Home: First Nationwide At-Home Delivery Service for Needle-Free Influenza Vaccination AstraZeneca has announced the launch of FluMist Home, a pioneering direct-to-consumer initiative that will allow individuals and families in much of the United States to receive FLUMIST®…
Nu-Tek BioSciences to Showcase 100% Animal-Free Peptones and Yeast Extracts at BPI East 2025, Driving the Future of Sustainable Cell Culture and Fermentation In an era where biopharmaceutical manufacturers are under increasing pressure to innovate while adhering to higher safety,…
Pfizer and Astellas Announce Landmark Phase 3 Results for PADCEV™ Plus KEYTRUDA™ in Muscle-Invasive Bladder Cancer, Marking Potential Paradigm Shift in Treatment for Cisplatin-Ineligible Patients Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura)…
Stoke Therapeutics and Biogen Dose First Patient in Pivotal Phase 3 EMPEROR Study of Zorevunersen, an Investigational Disease-Modifying Therapy for Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering RNA-based medicines to restore protein expression, and Biogen Inc.…
Melinta Therapeutics to Be Acquired by CorMedix in $300 Million Deal, Marking a Major Milestone in the Acute Care Pharmaceutical Sector Melinta Therapeutics, LLC (“Melinta”), a leading commercial-stage pharmaceutical company known for delivering innovative therapies for acute and life-threatening illnesses,…
